Aptevo Therapeutics Inc. (APVO) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 35K | 81K | 0 | 0 | 0 | 71K | 0 | 0 | 106K | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -35K | -81K | 0 | 0 | 0 | -71K | 0 | 0 | -106K | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | -14.08% | - | - | 100% | - | - | - | - | - | - | - |
| Operating Expenses | 6.8M | 5.92M | 7.61M | 6.23M | 6.48M | 6.31M | 5.21M | 6.02M | 6.88M | 6.38M | 6.56M | 8.18M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 2.91M | 2.46M | 3.57M | 2.9M | 2.85M | 2.5M | 2.11M | 2.38M | 3.23M | 2.79M | 2.67M | 2.72M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 3.89M | 3.54M | 4.04M | 3.33M | 3.63M | 3.88M | 3.1M | 3.64M | 3.65M | 3.59M | 3.89M | 5.46M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | -81K | 0 | 0 | 0 | -71K | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -6.84M | -6M | -7.61M | -6.23M | -6.48M | -6.38M | -5.21M | -6.02M | -6.98M | -6.38M | -6.56M | -8.18M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -5.51% | 6.05% | -45.98% | -3.35% | 7.2% | 0.03% | 20.55% | 26.34% | 9.97% | 16.92% | 15.71% | -8.15% |
| EBITDA | -6.8M | -5.92M | -7.56M | -6.18M | -6.42M | -6.31M | -5.13M | -5.93M | -6.88M | -6.27M | -6.44M | -8.03M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -5.97% | 6.27% | -47.42% | -4.11% | 6.66% | -0.69% | 20.33% | 26.1% | 9.25% | 16.68% | 14.86% | -10.18% |
| D&A (Non-Cash Add-back) | 35K | 81K | 49K | 49K | 61K | 71K | 84K | 91K | 106K | 116K | 123K | 150K |
| EBIT | -6.84M | -6M | -7.55M | -6.23M | -6.48M | -6.38M | -5.21M | -6.02M | -6.98M | -6.38M | -6.56M | -8.18M |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 140K | 190K | 61K | 22K | 72K | 70K | 112K | 141K | 149K | 188K | 227K | 230K |
| Pretax Income | -6.7M | -5.81M | -7.55M | -6.2M | -6.41M | -6.31M | -5.1M | -5.88M | -6.83M | -6.2M | -6.33M | -7.95M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -6.7M | -5.81M | -7.55M | -6.2M | -6.41M | -6.31M | -5.1M | -5.88M | -6.83M | -5.9M | -6.33M | -7.95M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -4.51% | 8.02% | -47.99% | -5.46% | 6.23% | -6.93% | 19.47% | 25.98% | -346.45% | -27.16% | 17.14% | -128.38% |
| Net Income (Continuing) | -6.7M | -5.81M | -7.55M | -6.2M | -6.41M | -6.31M | -5.1M | -5.88M | -6.83M | -6.2M | -6.33M | -7.95M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 293K | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -6.41 | -159.33 | -40.13 | -151.29 | -1581.72 | -1558.04 | -6441.29 | -22262.00 | -132553.00 | -177705.00 | -295114.00 | -718610.00 |
| EPS Growth % | 99.59% | 89.77% | 99.38% | 99.32% | 98.81% | 99.12% | 97.82% | 96.9% | -157.27% | 57.76% | 66.47% | -121.99% |
| EPS (Basic) | -6.41 | -159.33 | -40.13 | -151.29 | -1581.72 | -1558.04 | -6441.29 | -22262.00 | -132553.00 | -177705.00 | -295114.00 | -718610.00 |
| Diluted Shares Outstanding | 1.06M | 3.15K | 224.95K | 41.01K | 4.05K | 4.05K | 792 | 264 | 52 | 33 | 21 | 11 |
| Basic Shares Outstanding | 1.06M | 3.15K | 224.95K | 41.01K | 4.05K | 4.05K | 792 | 264 | 52 | 33 | 21 | 11 |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |